In a recent study, COL22A1 was identified as part of a group of extracellular matrix molecules that show elevated expression in the TME of GBM, suggesting its involvement in regulating the complex angiogenic processes within GBM and potentially impacting patient survival outcomes (25). Here, COL22A1 is linked to glioblastoma.